+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens



Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens



Archives of Dermatology 138(9): 1165-1171



To establish a safe and efficacious dosing regimen for the treatment of primary nodular basal cell carcinoma (BCC) using 5% imiquimod cream. Two phase 2 studies were conducted: a 6-week, randomized, open-label, dose-response study evaluating 4 dosing regimens and a 12-week, randomized, vehicle-controlled, double-blind, dose-response study evaluating 4 dosing regimens. Twenty-four public and private dermatology clinics in Australia and New Zealand (6-week study) and the United States (12-week study) participated. The study populations comprised 99 patients enrolled in the 6-week study and 92 patients in the 12-week study. Patients were at least 18 years old and had a biopsy-confirmed diagnosis of nodular BCC. In the 6-week study, imiquimod was applied once daily for 3 or 7 days per week or twice daily for 3 or 7 days per week. In the 12-week study, imiquimod or placebo cream (vehicle) was applied once daily for 3, 5, or 7 days per week, or twice daily for 7 days per week. The entire tumor area was excised 6 weeks after treatment and examined histologically for evidence of remaining BCC. The proportion of patients having no histologic evidence of BCC in the posttreatment excision specimen. Dosing once daily for 7 days per week resulted in the highest clearance rate, with 25 (71%) of 35 and 16 (76%) of 21 patients showing clearance of their tumor in the 6- and 12-week studies, respectively. Topical 5% imiquimod cream is well tolerated and most effective in treating nodular BCC when applied once daily for 7 days per week for either 12 or 6 weeks.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 045929451

Download citation: RISBibTeXText

PMID: 12224977


Related references

Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: Randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology 147(6): 1227-1236, 2002

Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage. Journal of Drugs in Dermatology 6(9): 910-914, 2007

Imiquimod cream efficacy in the treatment of periocular nodular basal cell carcinoma: a non-randomized trial. Bmc Ophthalmology 15: 35, 2015

A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. Journal of Dermatological Treatment 19(2): 111-117, 2008

An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. Australasian Journal of Dermatology 47(1): 46-48, 2006

A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. Journal of the American Academy of Dermatology 57(4): 616-621, 2007

Imiquimod 5% Cream as Pre-Treatment of Mohs Micrographic Surgery for Nodular Basal Cell Carcinoma in the Face, A Prospective Randomized Controlled Study Imiquimod As Pre-Treatment of Mohs. 2012

Case study: Imiquimod 5% cream in the treatment of a large nodular basal cell carcinoma. Dermatology Nursing 21(2): 86-87, 2009

Imiquimod 5% cream for the treatment of large nodular basal cell carcinoma at the medial canthal area. Indian Journal of Ophthalmology 65(1): 48-51, 2017

Complete remission of nodular basal cell carcinoma after combined treatment with photodynamic therapy and imiquimod 5% cream. Dermatology Online Journal 14(2): 25, 2008

Treatment of infiltrating basal cell carcinoma with the combination of intralesional IFNalpha-2b and topical imiquimod 5% cream. International Journal of Dermatology 48(2): 214-215, 2009

Long-term outcome after treatment with 5% topical imiquimod cream in patients with basal cell carcinoma of the eyelids. Graefe's Archive for Clinical and Experimental Ophthalmology 249(1): 121-125, 2011

Successful Treatment of Giant Basal Cell Carcinoma with Topical Imiquimod 5% Cream with Long Term Follow-up. Indian Journal of Dermatology 59(6): 575-578, 2014

Immunotherapy With Imiquimod 5% Cream for Eyelid Nodular Basal Cell Carcinoma. Yearbook of Ophthalmology 2007: 231-232, 2007

Immunotherapy with imiquimod 5% cream for eyelid nodular basal cell carcinoma. American Journal of Ophthalmology 140(6): 1136-1139, 2005